Vir Biotechnology (VIR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VIR Vir Biotechnology

Watchlist

7.380
-0.360-4.65%

Trading Oct 7 14:29 ET

1.01BMarket Cap-2061P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Vir Biotechnology, Inc. (NASDAQ:VIR) Is Largely Controlled by Institutional Shareholders Who Own 53% of the Company
Yahoo FinanceOct 5 09:52 ET
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Seeking AlphaOct 4 14:02 ET
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
BusinesswireOct 3 16:00 ET
Executive Reshuffles: LLY, S and RY Companies in Focus
Seeking AlphaSep 14 16:21 ET
Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer
BusinesswireSep 10 08:05 ET
Express News | Vir Biotechnology Appoints Jason O’byrne as Chief Financial Officer
ReutersSep 10 08:05 ET

Comments

QMengColdJoke

Sep 12 10:43

Very displeased cfo pick

$Vir Biotechnology (VIR.US)$ now you wany to sell company. But f you we have 10 dollar per share in equity and that is in cash. Cutting edge science, at least worth 10 dollar. You want to sell right now for how much? 10 dollar? I would sue you if you sell company below 20 dollar.
Firstly of first you need to pump to 20

Trytosaveabit

Sep 9 15:10

Update

$Vir Biotechnology (VIR.US)$ $Sanofi (SNY.US)$ Reuters· 4 mins ago
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

QMengColdJoke

Aug 1 17:05

So no more HIV no more covid?

$Vir Biotechnology (VIR.US)$ Good news is my position in GILD is safe. Sick but hell if you boost price to 20, I’ll love to leave. Oncology is crowded path, bad idea.
your own platform is most valuable and made 2 Billion for the company. You just let people go…

Trytosaveabit

Jun 26 07:17

News

$Vir Biotechnology (VIR.US)$ Vir Biotechnology Receives FDA Ind Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Trytosaveabit

Jun 5 04:45

Update

$Vir Biotechnology (VIR.US)$ Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

VIR Vir Biotechnology

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target